Back to search results

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Abroad (travel likely)RecruitingPHASE1

Conditions

Myelofibrosis · Essential Thrombocythemia · MPN

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

    Contact: Study coordinator (Gabriela Bello, BS) · gabriela.bello@mssm.edu · 212-241-0463
    Contact: Principal Investigator (Marina Kremyanskaya, MD, PhD)
Study leads

  • Marina Kremyanskaya, MD, PhD

    Principal Investigator

    Icahn School of Medicine at Mount Sinai

  • Nina Bhardwaj, MD, PhD

    Study Chair

    Icahn School of Medicine at Mount Sinai

  • Camelia Iancu-Rubin, PhD

    Study Chair

    Icahn School of Medicine at Mount Sinai

View source on ClinicalTrials.gov(opens in a new tab)